JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS最新文献_第2页

9. Current Status of Cancer Genenomic Medicine in Japan 9. 日本癌症基因组医学的现状

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_162

C. Kondo

引用次数: 0

5 ．オンコロジックエマージェンシー（Oncologic Emergency） 5。逻辑关系(Oncologic Emergency)

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_142

Takuya HONDA

引用次数: 0

7. What Staff Caring for Cancer Patients Need to Know About Evaluating Adverse Events in Oncology Clinical Trials 7.护理癌症患者的工作人员需要了解的关于评估肿瘤临床试验中的不良事件的信息

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_153

M. Yamazaki

引用次数: 0

8 ．がん薬物療法と薬物相互作用 8.癌症药物疗法与药物相互作用

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_157

Kazuhiro Yamamoto

引用次数: 0

Comparison of the Quality of Phase Ⅲ Non-commercial Clinical Trials in Japan, the United States, and the United Kingdom before the Implementation of the New Japanese Clinical Trials Act 日本新临床试验法实施前日本、美国和英国Ⅲ期非商业临床试验的质量比较

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_95

Sachiko YAMAUCHI, Yoshikazu MIWA, Masayuki IKEDA, Shinichiro UEDA

{"title":"Comparison of the Quality of Phase Ⅲ Non-commercial Clinical Trials in Japan, the United States, and the United Kingdom before the Implementation of the New Japanese Clinical Trials Act","authors":"Sachiko YAMAUCHI, Yoshikazu MIWA, Masayuki IKEDA, Shinichiro UEDA","doi":"10.3999/jscpt.54.3_95","DOIUrl":"https://doi.org/10.3999/jscpt.54.3_95","url":null,"abstract":"Recent research misconduct, represented by the valsartan scandal, has raised questions about the quality of non-commercial trials not for regulatory approval in Japan. Unlike in the US and Europe, non-commercial clinical trials are not regulated by law in Japan, which was believed to be a reason why quality could not be guaranteed. However, until now, few studies have compared the quality of clinical studies among countries. In this study, the quality of Japanese non-commercial phase Ⅲ trials before the implementation of the Clinical Trials Act (CTA) in 2018 was compared with Western non-commercial trials registered in the database using study design as quality indicators. The study found a lower proportion of randomized, controlled trials (RCTs) (70％ in Japan, 89％ in the US, and 88％ in the UK) and fewer blinded designs (46％ in Japan, 59％ in the US, and 52％ in the UK) in non-commercial trials in Japan. Single-arm trials not for either cancer or rare diseases, which are usually considered low quality because of a lack of fair comparison, were more common in Japan (82％) than in the US (76％) and the UK (50％). In terms of endpoint setting, most non-commercial trials in Japan had surrogate endpoints, with only a few trials using true endpoints (5％) compared to the US (24％) and the UK (40％). A comparison of these quality indicators in Japanese non-commercial trials before and after the CTA implementation showed no increases in the proportion of RCT and blinded designs, but an increase in the proportion of trials using true endpoints and appropriate use of single-arm design. In conclusion, the lack of legal regulation in Japan may have indirectly affected the quality of non-commercial phase Ⅲ trials in Japan at the time. Implementation of the CTA has contributed to some quality improvements, but the effect is limited at present.","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3 ．免疫チェックポイント阻害薬の副作用管理 3。免疫检查点抑制剂的副作用管理

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_130

Hitomi Watanabe

引用次数: 0

1. The Essentials of Cancer Drug Therapy 1. 癌症药物治疗要点

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_115

Yoko Ishiguro, Y. Ando

引用次数: 0

6. Pharmacological Therapy for Cancer Pain 6. 癌症疼痛的药理治疗

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_147

Takashi YAMAGUCHI

引用次数: 0

Investigative Research on the Importance of Collecting and Examining Drug Information from a Scientific and Objective Point of View 从科学、客观的角度探讨药品信息收集与审查的重要性

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_105

Kaori Takashima, T. Aoyama, Masayo Komoda, A. Saitoh, Hideyo Takahashi, M. Nishikawa, S. Shimada, Tatsunori Suzuki, Y. Mano, R. Takasawa

引用次数: 0

第29回臨床薬理学講習会（2022年度）記録「がん薬物療法を受けている患者を診る」第29回临床药理学讲习会(2022年度)记录“诊断接受癌症药物疗法的患者”

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2023-05-31 DOI: 10.3999/jscpt.54.3_113

引用次数: 0